BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23425867)

  • 1. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
    Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
    Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
    Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
    Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
    Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
    Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
    Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
    Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
    J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
    Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
    Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Distinction between benign and malignant pheochromocytomas].
    Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
    Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
    Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
    Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
    Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
    Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in pheochromocytoma.
    Clarke MR; Weyant RJ; Watson CG; Carty SE
    Hum Pathol; 1998 May; 29(5):522-6. PubMed ID: 9596278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytomas, PASS, and immunohistochemistry.
    Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
    Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.